LENZ Therapeutics, Inc. (LENZ)
| Market Cap | 291.28M |
| Revenue (ttm) | 19.09M |
| Net Income (ttm) | -82.13M |
| Shares Out | 31.35M |
| EPS (ttm) | -2.85 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 849,249 |
| Open | 9.68 |
| Previous Close | 9.76 |
| Day's Range | 9.19 - 9.96 |
| 52-Week Range | 8.25 - 50.40 |
| Beta | 2.30 |
| Analysts | Strong Buy |
| Price Target | 44.00 (+373.63%) |
| Earnings Date | May 6, 2026 |
About LENZ
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for LENZ stock is "Strong Buy." The 12-month stock price target is $44.0, which is an increase of 373.63% from the latest price.
News
LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom
MHRA submission follows EMA validation of the VIZZ MAA in March 2026 Sixth ex-U.S. regulatory submission for VIZZ underscores accelerating global expansion SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -...
LENZ Therapeutics Earnings Call Transcript: Q4 2025
LNZ100/VIZZ is off to a strong launch, with robust physician adoption, high refill rates, and encouraging early patient persistence. Financially, the company is well-capitalized, investing heavily in sales, marketing, and DTC campaigns, with expectations for accelerated growth in the second half of 2026.
LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
Launched VIZZ ® (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of $1.6 million in the first quarter of launch On pace for ove...
LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalm...
LENZ Therapeutics Transcript: Leerink Global Healthcare Conference 2026
A novel presbyopia eye drop has shown rapid, sustained efficacy and strong safety in both clinical and real-world use, outpacing competitors in adoption and refill rates. Early DTC campaigns and a growing prescriber base are driving awareness, with international expansion underway.
LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia
MAA submission to the European Medicines Agency represents a key regulatory milestone in LENZ's strategy to expand global access to VIZZ Submission of MAA in Europe results in the fifth ex-U.S. regula...
LENZ Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
A new presbyopia eye drop launched in October is showing strong efficacy and safety, with rapid adoption among doctors and patients. Direct-to-consumer campaigns and sales force expansion are driving awareness, and early refill rates are encouraging. The product targets a large, underpenetrated market with significant growth potential.
LENZ Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmo...
New FDA-Approved Eye Drop Sparks Fresh Competition For LENZ Therapeutics' Drug
On Wednesday, the U.S. Food and Drug Administration (FDA) approved Tenpoint Therapeutics Ltd.'s Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, previously known as Brimoch...
LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign
Struggling to see up close? VIZZ is a revolutionary, once-daily eye drop and alternative to reading glasses to restore near vision for up to 10 hours
LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates
Launched VIZZ™ (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-November 2025
LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East
SAN DIEGO and DUBAI, United Arab Emirates, Jan. 05, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lunatus Marketing & Consulting FZCO (“Lunatus”) today announced an exclusive dis...
LENZ Therapeutics Transcript: Citi Annual Global Healthcare Conference 2025
The product's launch has seen strong early adoption, with rapid, long-lasting efficacy and minimal side effects. A major DTC campaign featuring Sarah Jessica Parker will begin in Q1, aiming to drive new patient starts, while global expansion and robust supply chain strategies support future growth.
LENZ Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
A newly approved presbyopia eye drop achieved rapid adoption, with over 2,500 doctors prescribing and strong early script numbers. The company is focused on expanding awareness, launching a DTC campaign in Q1, and leveraging a robust cash position to support U.S. and international growth.
LENZ Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
VIZZ achieved rapid market adoption with high brand awareness, strong early prescription volume, and positive feedback on efficacy and safety. The upcoming DTC campaign, led by Sarah Jessica Parker, targets key demographics and is expected to accelerate growth within months of launch.
LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia
Submission of NDA in South Korea by Lotus Pharmaceutical results in the second ex-U.S. regulatory submission for VIZZ Submission of NDA in South Korea by Lotus Pharmaceutical results in the second ex-...
LENZ Therapeutics Earnings Call Transcript: Q3 2025
FDA approval and U.S. launch of VIZZ drove strong early adoption, with over 5,000 paid prescriptions in October and high eye care professional engagement. Financials reflect a ramp in commercial spend, robust cash reserves, and ex-U.S. partnership revenue.
LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
VIZZ TM (aceclidine ophthalmic solution) 1.44% received FDA approval for the treatment of presbyopia Commercial product launch initiated in October 2025 with broad product availability in mid-Q4 2025 ...
LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025
SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmo...
LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States
VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025 VIZZ is the ...
LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States
VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025 VIZZ is the ...
LENZ Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
A newly approved ophthalmic drop for presbyopia demonstrated rapid, sustained efficacy in clinical trials, with 93% of patients achieving 20/40 vision or better. The commercial strategy targets both doctors and consumers, leveraging lessons from prior market launches and focusing on refill rates and broad patient appeal.
LENZ Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Viz, a new presbyopia eyedrop, is launching with FDA approval, targeting full-day near vision restoration and a cash-pay model. Sampling starts in October, with broad commercial availability by mid-Q4. Strong clinical efficacy, physician enthusiasm, and global expansion plans set the stage for rapid adoption.
LENZ Therapeutics Transcript: Cantor Global Healthcare Conference 2025
VIZZ, a newly FDA-approved presbyopia eye drop, is set for U.S. launch with a focus on sampling, e-pharmacy distribution, and a strong DTC push in Q1. Early revenue is expected to be modest, but consensus projects rapid growth as the product differentiates itself from competitors through efficacy and convenience.
LENZ Therapeutics Transcript: Citi's Biopharma Back to School Conference
Vizz, a once-daily eye drop for presbyopia, is launching with a focus on optometrists, a phased commercial strategy, and strong differentiation from competitors. Early adoption is expected among contact lens wearers, post-LASIK patients, and active aging consumers, with international expansion planned.